Market Update: Eli Lilly & Company (NYSE:LLY) – Eli Lilly and Company and AstraZeneca Announce Continuation of Pivotal Clinical Trial for People with Early Alzheimer’s Disease

[PR Newswire] – The AMARANTH independent data monitoring committee recommended the study continue without modification after a scheduled interim safety analysis was conducted. “This is an important and meaningful step forward on the path to better understand the Alzheimer’s puzzle,” said Phyllis Ferrell, vice president and global development leader for Alzheimer’s disease at Lilly. Read more on this. Eli Lilly and Company (LLY) , valued at $78.82B, started trading this morning at $75.28. Shares have traded today between $74.01 and $75.28 per share with a trailing 52-week range being $67.88 to $92.85. LLY shares are currently priced at 21.07x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s -5.27x forward p/e ratio. And for passive income investors, the company pays shareholders $2.04 per share annually in dividends, yielding 2.79%. In a review of the consensus earnings estimate this quarter, 18 sell-side analysts are looking at $0.84 per share, which would be $0.03 worse than the year-ago quarter and a $0.02 sequential decrease. The full-year EPS estimate is $3.54 which would be a $0.11 improvement than last year’s full-year earnings. The quarterly earnings estimate is predicated on a consensus revenue forecast of $4.81 Billion. If reported, that would be a 3.66% increase over the year-ago quarter. In terms of ratings, Societe Generale Initiated LLY at Hold (Apr 6, 2016). Previously, BMO Capital Markets upgraded LLY from Market Perform to Outperform. The average price target for LLY shares is $94.55, which is 25.60% above where the stock opened this morning. See more in (NYSE:LLY) Similar Articles: Company Update: Eli Lilly & Company (NYSE:LLY) – Technical Pointers on Drug Manufacturers – Major Stocks – Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, and AstraZeneca Stock Update: Eli Lilly & Company (NYSE:LLY) – Lilly and Incyte Announce Submission of New Drug Application to FDA for Oral Once-Daily Baricitinib for Treatment of Moderate-to-Severe Rheumatoid Arthritis Company Update (NYSE:LLY): Europe recommends lung cancer drugs from AstraZeneca, Lilly